MetaCap

Amneal Pharmaceuticals (AMRX) vs Kiniksa Pharmaceuticals International (KNSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiniksa Pharmaceuticals International (KNSA) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 125.8% versus a gain of 76.7%. Over five years, KNSA leads with a +706.0% price change compared with +396.9% for AMRX. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $7.36 billion), about 1.0 times the size.

On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 45.9x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 2.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRX+76.74%KNSA+125.82%
+145%+64%-16%
Nov 21, 20251 yearNov 20, 2026
AMRX+357.14%KNSA+669.63%
+728%+309%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRX versus KNSA key metrics
MetricAMRXKNSA
Share price$21.12$93.90
Market cap$7.36B$7.38B
1-day change-1.26%+0.38%
YTD return+67.62%+127.62%
1-year return+76.74%+125.82%
5-year return+396.94%+705.97%
P/E ratio (TTM)52.8071.13
Forward P/E17.1345.91
EPS (TTM)$0.40$1.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.02B$677.56M
Revenue growth (YoY)+8.05%+60.09%
Net income (latest FY)$72.06M$59.01M
Gross margin36.88%88.54%
Operating margin13.05%11.40%
Net margin2.39%8.71%
52-week high$22.13$99.31
52-week low$11.71$37.02
Distance from 52-week high-4.54%-5.45%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+15.01%+18.82%
Average volume3.16M664.53K
Shares outstanding348.41M48.84M
Employees8,700366
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KNSA has outperformed AMRX by 49.1 percentage points over the past year.
  • Kiniksa Pharmaceuticals International trades at a higher earnings multiple (71.1x vs 52.8x trailing P/E).
  • Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
  • Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +8.05%).

About Amneal Pharmaceuticals

AMRX stock →

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees

About Kiniksa Pharmaceuticals International

KNSA stock →

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees

AMRX vs KNSA FAQ

Which is bigger, Amneal Pharmaceuticals or Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $7.36B for Amneal Pharmaceuticals (AMRX).

Which stock has performed better over the past year, AMRX or KNSA?

KNSA returned +125.82% over the past 12 months, compared with +76.74% for AMRX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AMRX or KNSA?

AMRX has the lower trailing P/E at 52.8, versus 71.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Amneal Pharmaceuticals and Kiniksa Pharmaceuticals International in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons